Thursday, 20 June 2024

Taiwan's Medigen explores EUA for COVID-19 vaccine in different countries

18 October 2021 | News

Provides data to support MVC-COV1901 for entering phase 3 efficacy trials

image credit- shutterstock

image credit- shutterstock

Taiwan-based Medigen Vaccine Biologics Corporation has recently stated that MVC-COV1901, a recombinant protein vaccine containing pre-fusion-stabilised spike protein S-2P adjuvanted with CpG 1018 and aluminium hydroxide, has been shown to be well tolerated with a good safety profile in healthy adults aged 20–49 years in a phase 1 trial, and provided a good cellular and humoral immune responses.

The company has presented the interim safety, tolerability, and immunogenicity results of a phase 2 clinical trial of the MVC-COV1901 vaccine in Taiwan.

Medigen has reported the results of the interim analysis of the phase 2 clinical trial of MVC-COV1901 (15 µg S-2P protein); the first large-scale trial to evaluate the safety and immunogenicity profiles of MVC-COV1901 in 3844 adults aged 20 years and older.

MVC-COV1901 was shown to have a good safety and immunogenicity profile. The current data support MVC-COV1901 to enter phase 3 efficacy trials, and could enable regulatory considerations for emergency use authorisation (EUA) in different countries, as has been done in Taiwan.

By sharing the phase 2 clinical data and the proposed correlates of protection methods with other COVID-19 vaccine developers in the community, Medigen hopes to expedite the development and approval of more COVID-19 vaccine candidates to increase global supply, and to thereby help the countries and regions most in need.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account